Robin A. E. Carr

Redx Pharma (United Kingdom) — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index4.7kcitations49works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemical Synthesis and Analysis(12), Computational Drug Discovery Methods(6), Analytical Chemistry and Chromatography(6), Asymmetric Synthesis and Catalysis(4), Microbial Natural Products and Biosynthesis(4)

Publications49 total

MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
Cell Reports·2025· 2 citedOpen Access
Abstract 2635: N-Myristolytransferase (NMT) inhibitors as novel potent payloads for antibody drug conjugates
Cancer Research·2023· 4 cited
Abstract 4871: Dysregulation of MYC-family proteins sensitizes cancers to NMT inhibition: identification of NMTi sensitivity and mechanism
Cancer Research·2023
<i>N</i> -myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers
2021· 6 citedOpen Access
Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo
Bioorganic & Medicinal Chemistry·2018· 9 citedOpen Access
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
PLoS ONE·2014· 250 citedOpen Access
Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency
Journal of Medicinal Chemistry·2007· 210 citedOpen Access
Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery
Journal of Medicinal Chemistry·2007· 138 citedOpen Access
Structure of PKA-PKB chimera complexed with 2-(4-chloro-phenyl)-2- phenyl-ethylamine
2007
STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-chloro-phenyl)-4-(4-(1H-pyrazol-4-yl)-phenyl)-piperidine
2007
Structure of PKA-PKB chimera complexed with 4-(4-chloro-phenyl)-4-(4- (1H-pyrazol-4-yl)-phenyl)-piperidine
2007
Structure of PKA-PKB chimera complexed with 5-methyl-4-phenyl-1H- pyrazole
2007
Application of Fragment Screening by X-ray Crystallography to the Discovery of Aminopyridines as Inhibitors of β-Secretase
Journal of Medicinal Chemistry·2007· 141 citedOpen Access
Chapter 28 Fragment-Based Lead Discovery
Annual reports in medicinal chemistry·2007· 24 cited
Fragment-based lead discovery: leads by design
Drug Discovery Today·2005· 337 cited
CCDC 256849: Experimental Crystal Structure Determination
The Cambridge Structural Database·2005Open Access
Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation
Journal of Medicinal Chemistry·2004· 185 citedOpen Access
Fragment-based lead discovery
Nature Reviews Drug Discovery·2004· 789 cited
International Comparative Analysis of Time-out Decision Making Strategies Employed by Male University Basketball Coaches
Asian Journal of Physical Education & Recreation·2003· 1 citedOpen Access
A ‘Rule of Three’ for fragment-based lead discovery?
Drug Discovery Today·2003· 1.3k cited
page 1 of 3Next →

Frequent Co-authors

Miles Congreve(14), Steven M. Allin(8), E. W. COLLINGTON(8), Christopher W. Murray(7), Philip C. Bulman Page(7), Steven J. Woodhead(6), Anthony G. M. Barrett(6), Geoffrey Richardson(6), Jan Scicinski(6), Harren Jhoti(5), Gordon Saxty(5), Valério Berdini(5), Marcel L. Verdonk(5), Paul G. Wyatt(5), Robert Downham(5), Michelle D. Garrett(5), David Barford(4), Stephen V. Attwood(4), N. D. A. WALSHE(4), Harry Finch(4)